Lilly Archives -

China’s emergence as an R&D powerhouse means that the country is quickly adding a number of drug candidates

FDA’s treatment of China-developed drugs spurs demands for multiregional clinical trials

https://pharmaphorum.com/market-access-2/fdas-treatment-of-china-developed-drugs-spurs-demands/

Market Access/ News/ News

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

Joy Persaud Diabetes, Lilly, Mounjaro, Type 2 diabetes 0 Comment

Blood sugar control drug Mounjaro has been granted US regulatory approval, giving type 2 diabetics another way to

Lilly’s new drug Mounjaro (tirzepatide ) wins US FDA approval

https://pharmaphorum.com/news/lillys-new-drug-mounjaro-tirzepatide-wins-us-fda-approval/

R&D/ Views & Analysis/ Views and analysis

Early diagnosis key to future Alzheimer’s treatments

mike.hammerton@pharmaphorum.com Aduhelm, Alzheimer's, Alzheimer's Research UK, Biogen, Lilly, RetiSpec 0 Comment

The approval of Biogen’s Alzheimer’s treatment could herald a new generation of therapies, but before that can happen,

Early diagnosis key to future Alzheimer’s treatments

https://pharmaphorum.com/r-d/early-diagnosis-key-to-future-alzheimers-treatments/

News/ News/ R&D

Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumab

Richard Staines Lilly, osteoarthritis, pain, Pfizer, tanezumab 0 Comment

After more than a decade of fraught clinical development it looks like the end of the line for

Thumbs-down from FDA experts for Pfizer/Lilly’s painkiller tanezumab

https://pharmaphorum.com/news/fda-experts-give-thumbs-down-for-pfizer-lillys-painkiller-tanezumab/

Market Access/ News/ News/ News/ R&D

US buys Lilly COVID antibody, as effectiveness questions remain

George Underwood antibody, bamlanivimab, coronavirus, COVID-19, Eli Lilly, Lilly, US 0 Comment

The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy bamlanivimab for $375 million

US buys Lilly COVID antibody, as effectiveness questions remain

https://pharmaphorum.com/news/us-buys-300000-doses-lilly-covid-antibody/

News/ News/ R&D

Lilly begins trial of COVID-19 antibody treatment

George Underwood AbCellera, coronavirus, COVID-19, Lilly 0 Comment

Eli Lilly has started dosing patients in the world’s first trial for a medicine specifically designed to attack

Lilly begins trial of COVID-19 antibody treatment

https://pharmaphorum.com/news/lilly-begins-trial-of-covid-19-antibody-treatment/

News/ News/ R&D

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

Phil Taylor Humira, Lilly, psoriatic arthritis, Taltz 0 Comment

Eli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been

Lilly’s Taltz scrapes win against Humira in psoriatic arthritis

https://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/

Market Access/ News/ News

Lilly’s migraine drug gets key cluster headache approval

George Underwood cluster headache, Emgality, Lilly 0 Comment

The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving

Lilly’s migraine drug gets key cluster headache approval

https://pharmaphorum.com/news/lillys-migraine-drug-gets-key-cluster-headache-approval/

Market Access/ News/ News

Lilly cuts $1bn deal for Centrexion’s non-opioid painkiller

Phil Taylor Centrexion, Lilly, non-opioid painkiller 0 Comment

Eli Lilly has signed another bolt-on deal to bulk up its pipeline, this time paying $47.5 million upfront

Lilly cuts $1bn deal for Centrexion’s non-opioid painkiller

https://pharmaphorum.com/news/lilly-cuts-1bn-deal-for-centrexions-non-opioid-painkiller/

Trending

Lilly

Login